In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Kennedy Jr. earned more than $2.4 million as a consultant referring cases to the law firm Wisner Baum, government records show. Wisner Baum is suing Merck & Co. over allegations that the ...

Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

Tanzania President, Namibia President Elect and Merck Foundation Chief Executive Officer (CEO) named amongst 100 Most ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $98.28 which represents a slight increase of $0.83 or 0.85% from the prior close of $97.45. The stock opened at $97.42 and touched a ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...